{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+150+mg&page=2", "query": { "intervention": "Alirocumab 150 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+150+mg&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+150+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T08:41:38.894Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01709513", "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2012-09-30", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 41, "location_summary": "Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709513" }, { "nct_id": "NCT01623115", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 486, "start_date": "2012-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 26, "location_summary": "Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01623115" }, { "nct_id": "NCT03014830", "title": "Alirocumab and Reverse Cholesterol Transport", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atherosclerosis", "Coronary Heart Disease" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 28, "start_date": "2017-06-01", "completion_date": "2018-07-30", "has_results": false, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03014830" }, { "nct_id": "NCT02642159", "title": "Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Statins", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" }, { "name": "Nicotinic acid", "type": "DRUG" }, { "name": "Omega-3 fatty acids", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 413, "start_date": "2016-03-15", "completion_date": "2017-05-15", "has_results": true, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 57, "location_summary": "Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02642159" }, { "nct_id": "NCT02938949", "title": "Alirocumab in Patients With Acute Myocardial Infarction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Myocardial Infarction", "Hypercholesterolemia" ], "interventions": [ { "name": "alirocumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 20, "start_date": "2017-01", "completion_date": "2018-08-16", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938949" }, { "nct_id": "NCT01617655", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2012-06", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 14, "location_summary": "Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01617655" }, { "nct_id": "NCT01266876", "title": "Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2011-01", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2015-09-22", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 17, "location_summary": "Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266876" }, { "nct_id": "NCT03480568", "title": "Alirocumab in Patients on a Stable Dialysis Regimen", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemodialysis", "Peritoneal Dialysis", "Hypercholesterolemia", "Atherosclerotic Disease" ], "interventions": [ { "name": "Alirocumab 150 MG/ML [Praluent]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2018-05-01", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2020-02-12", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480568" }, { "nct_id": "NCT01954394", "title": "Open Label Study of Long Term Safety Evaluation of Alirocumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 986, "start_date": "2013-12-17", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954394" }, { "nct_id": "NCT07615166", "title": "Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Alirocumab 150 mg", "type": "DRUG" }, { "name": "Inclisiran", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 996, "start_date": "2025-05-22", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-05T08:41:38.894Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07615166" } ] }